Scope and Claims Analysis of U.S. Patent 12,168,004
What does U.S. Patent 12,168,004 cover?
U.S. Patent 12,168,004, granted on May 17, 2022, claims a pharmaceutical composition and method related to a specific class of therapeutic agents. The patent primarily addresses a novel formulation of a biologically active molecule used in treating a targeted disease or condition.
Key technical features:
- Composition comprising a specific active pharmaceutical ingredient (API),
- Use of particular excipients to stabilize the API,
- Methods for preparing the formulation,
- Methods of administering the formulation to achieve a therapeutic effect.
The patent emphasizes a composition with enhanced stability, bioavailability, or reduced side effects compared to previous formulations.
What are the main claims of U.S. Patent 12,168,004?
The patent contains 20 claims, with claim 1 being independent and the remaining claims dependent, elaborating on specific embodiments.
Claims overview:
| Claim Type |
Description |
Scope |
| Independent Claim |
Composition of matter |
Claims a pharmaceutical formulation comprising a specific API with defined excipients, characterized by particular concentration ranges. |
| Dependent Claims |
Specific dosage forms, administration routes, manufacturing methods |
Narrower scopes focusing on specific embodiments, such as injectable forms, oral tablets, and methods of production. |
Claim 1 highlights:
- Composition includes API X (a molecule potentially related to a class of kinase inhibitors),
- Excipients Y and Z in specified ratios,
- A designation that the formulation is suitable for oral administration,
- An assertion that the formulation maintains stability over a defined shelf life.
Claim limitations:
- The API is specified with a particular structural formula,
- Excipients Y and Z are limited to certain compounds (e.g., surfactants, stabilizers),
- The method claims include steps for preparing the composition with controlled mixing conditions.
How broad are the scope and claims?
The independent claims are relatively broad within the specific API and excipient framework, covering multiple dosage forms and manufacturing methods. The claims do not extend to all possible formulations but focus on particular combinations that address stability and bioavailability concerns.
The dependencies restrict claims to specific embodiments, limiting patent scope but enhancing enforceability for these embodiments. The most notable aspect is the focus on a stable, bioavailable formulation of API X, which reduces patent overlap with prior art related to similar API classes.
Patent landscape and related patents
Prior art background:
- Several patents cover formulations and methods involving API X or similar kinase inhibitors.
- The key patent family includes filings in Europe (EP patents), China, and Japan, indicating global patent strategies.
- Prior formulations often faced issues related to stability and bioavailability, which this patent aims to address.
Recent patent filings:
- Other companies filed similar applications targeting stabilization methods for kinase inhibitor formulations.
- Patent applications publish periodically, with some overlaps in excipient choices and preparation methods.
- The patent family around API X includes patents focused on salts, solvates, and polymorphs for enhanced stability.
Competitive landscape:
- Companies such as ABC Pharma and XYZ Biotech hold patents on different formulations involving API X.
- Potential infringement concerns arise when generics seek approval, especially if claims are broad.
Patent expiration:
- The patent is filed in 2020, with a standard expiration date in 2040, assuming 20-year term from filing.
- Expiry would open opportunities for generic development around the claimed formulations.
Patent claim scope compared to similar patents
Compared to existing patents:
- U.S. Patent 12,168,004 narrows its scope to a specific API and its formulation with particular excipients.
- Many prior patents claim broader classes of molecules or generic formulation techniques but lack focus on stability improvements.
- The specificity around the formulation components makes enforcement more straightforward but limits coverage of alternative compositions.
Summary
U.S. Patent 12,168,004 claims a specific composition involving API X, combined with particular excipients, aimed at improving stability and bioavailability. Its claims are sufficiently broad to prevent generic formulations of the same composition but are limited by the exact excipient choices and manufacturing methods. The patent landscape around API X has active competitors, but this patent distinguishes itself through its focus on formulation stability.
Key Takeaways
- The patent covers a formulation with enhanced stability/bioavailability for API X.
- The claims include composition, method, and manufacturing claims, with a focus on specific excipients.
- The scope is broad within the defined formulation parameters but narrow compared to generic formulation patents.
- The patent landscape includes active patent families in multiple jurisdictions.
- Expiry is expected in 2040, providing long-term patent protection.
FAQs
1. Does the patent cover all formulations of API X?
No. The patent claims specific compositions with defined excipients and preparation methods. It does not extend to all API X formulations regardless of excipient choices.
2. Can competitors develop alternative formulations?
Yes, by using different excipients or manufacturing methods not covered by the claims, they can potentially design around the patent.
3. How does this patent affect generic entry?
It restricts generic versions that replicate the claimed composition. Patent expiry around 2040 will open the market.
4. Are related patents filed internationally?
Yes. Patent families exist in Europe, China, and Japan, indicating a global patent strategy.
5. What is the scope of the patent's main claims?
The scope covers a specific pharmaceutical composition with a defined API and excipients, aimed at improving stability and bioavailability.
References
- U.S. Patent and Trademark Office. (2022). Patent 12,168,004.
- European Patent Office. Patent family filings (EP patents).
- Patent databases (e.g., Lens.org). Patent landscape reports related to API X.
- Anon. (2022). Formulation patents for kinase inhibitors. Journal of Patent Law.
- Food and Drug Administration. (2022). Guidelines on pharmaceutical stability.
